Allosteric CDK2 Inhibitors for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective kinase inhibitors, particularly for cyclin-dependent kinase 2 (CDK2), is challenging due to structural homology at the ATP-binding site, and few high-affinity allosteric kinase inhibitors exist, limiting therapeutic options for cancer and non-hormonal contraceptive applications.
Innovation Solution
A series of allosteric inhibitors of CDK2 that bind to an allosteric pocket within the enzyme, demonstrating negative cooperativity with cyclin binding, as confirmed by X-ray crystallography, and are represented by specific compounds of Formula (I), which can be used to treat cancer and induce contraceptive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhibitors bind to the ATP-binding site of kinases, then they can effectively inhibit kinase activity, but selectivity is lost due to structural homology across different kinases
Solution Approach 1:
The patent uses an allosteric site as an intermediary binding location instead of the conventional ATP-binding site. This intermediary site allows the inhibitor to indirectly affect kinase activity while avoiding the structural homology problem, achieving both efficacy and selectivity simultaneously
Solution Approach 2:
The invention transitions from binding at the conserved ATP-binding site (one dimension) to binding at the allosteric site (another dimension). This dimensional shift in binding location allows the inhibitor to achieve selectivity while maintaining inhibition efficacy
2Adaptability or versatility
If allosteric inhibitors are developed to achieve selectivity, then specificity for particular kinase isoforms improves, but the number of available high-affinity inhibitors remains limited
Solution Approach 1:
The patent systematically varies chemical parameters in the compound structure (R1, R2, R3, R5, R6, R7, R8, R9, R10, R11 substituents) to generate multiple high-affinity allosteric inhibitors with different properties, thereby increasing the quantity of available selective inhibitors
Solution Approach 2:
The core allosteric binding scaffold is designed to be universal across CDK2 isoforms, while allowing for targeted modifications. This multi-functional approach enables a single compound design strategy to address multiple kinase isoform targets
Data Source
AI summary
The invention provides a compound of Formula (I):or a salt thereof, wherein R1-R3, R5-R11, Z, X, and L have any of the values described in the specification, as well as compositions comprising a compound of Formula (I). The compounds are useful as cyclin-dependent kinase 2 (CDK2) inhibitors.